Intrauterine growth restriction

K Haram1, E Søfteland, R Bukowski

  • 1Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway. kjell.haram@broadpark.no

Insights

This review covers screening, diagnosis, and treatment for intrauterine growth restriction (IUGR). Early detection and specific interventions like aspirin can improve outcomes for high-risk pregnancies.

Area of Science:

  • Obstetrics and Gynecology
  • Fetal Medicine

Background:

  • Intrauterine growth restriction (IUGR) is a significant concern in perinatal medicine.
  • Accurate screening and diagnosis are crucial for effective management.

Purpose of the Study:

  • To review current evidence on the screening, diagnosis, prophylaxis, and treatment of IUGR.
  • To identify best practices for managing fetal growth restriction.

Main Methods:

  • Literature search of PubMed and Cochrane databases.
  • Systematic review of studies on IUGR screening, diagnosis, and management.

Main Results:

  • Screening relies on risk factors and symphysis-fundus height; diagnosis is confirmed by ultrasonography.
  • Improved diagnostic accuracy may be achieved with customized growth curves, charts, and advanced Doppler ultrasonography.
  • Prophylaxis with acetylsalicylic acid or heparin, and targeted treatment of infections or asthma, may reduce IUGR incidence.
  • Antenatal corticosteroids reduce perinatal morbidity and mortality; bed rest is ineffective.

Conclusions:

  • Current screening and diagnostic methods for IUGR are established but can be enhanced.
  • Specific prophylactic and therapeutic strategies show promise in reducing IUGR incidence and improving perinatal outcomes.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...